A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease — Gerasimos Filippatos (2016) | RDL Network
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Article 2016 en
Authors
GF
Gerasimos Filippatos
SA
Stefan D. Anker
MB
Michael Böhm
Abstract
1 min read
Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone. The finding of reduced clinical events in the finerenone 10→20 mg group should be further explored in a large outcomes trial.
Inder S. Anand, Changhong Yu, Marc A. Pfeffer, John J.V. McMurray, Akshay S. Desai, Scott D. Solomon, Dirk J. ban Veldhuisen, Sunfa Cheng, Kurt Olson, Aldo Maggioni, Karl Swedberg, James B. Young
Toru Kondo, Pardeep S. Jhund, Inder S. Anand, Akshay S. Desai, Carolyn S.P. Lam, Aldo Maggioni, Felipe A Martinez, M REDFIELD, Jean‐Lucien Rouleau, D.J. van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Milton Packer, Scott D. Solomon, John J.V. McMurray
Paul Welsh, Lei Kou, Changhong Yu, Inder S. Anand, Dirk J. van Veldhuisen, Aldo Maggioni, Akshay S. Desai, Scott D. Solomon, Marc A. Pfeffer, Sunfa Cheng, Lars Gullestad, Pål Aukrust, Thor Ueland, Karl Swedberg, James B. Young, Michael W. Kattan, Naveed Sattar, John J.V. McMurray
Stephen J. Greene, Gregg C. Fonarow, Scott D. Solomon, Haris Subačius, Andrew P. Ambrosy, Muthiah Vaduganathan, Aldo Maggioni, Michael Böhm, Eldrin F. Lewis, Faı̈ez Zannad, Javed Butler, Mihai Gheorghiade
Stephen J. Greene, Aldo Maggioni, Gregg C. Fonarow, Scott Solomon, Michael Böhm, Albert Kandra, Margaret F. Prescott, Bernard Reimund, Tsushung A. Hua, Anastasia Lesogor, Faı̈ez Zannad, Mihai Gheorghiade
Discussion(0)
No comments yet. Be the first to comment.